Study examines canine anaphylaxis outcomes without early epinephrine
Bottom line
A new retrospective study in the Journal of Veterinary Emergency and Critical Care looked at 49 dogs with severe anaphylaxis treated between January 2019 and December 2023 that did not receive epinephrine as part of early treatment. The authors found an overall survival-to-discharge rate of 91.8%, even though these were severe cases managed with either late epinephrine or no epinephrine at all. The study also found that higher shock index and higher blood lactate were associated with worse outcomes and greater resource use, suggesting those measures may help identify the sickest patients earlier. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the findings are notable because epinephrine remains widely described as first-line therapy for canine anaphylaxis, yet this case series suggests some dogs can still survive without early epinephrine, likely reflecting heterogeneity in presentation, timing, and response to aggressive supportive care. That doesn’t change the standard approach: veterinary emergency references and expert commentary still frame epinephrine as the treatment of choice, with antihistamines and glucocorticoids as adjuncts rather than substitutes. What this paper may do is sharpen triage thinking around prognostic markers, especially lactate and shock index, in cases where treatment is delayed, incomplete, or atypical. (dvm360.com)
What to watch: Watch for follow-up studies that compare early epinephrine versus delayed or omitted epinephrine directly, ideally in multicenter cohorts with standardized severity scoring. (pubmed.ncbi.nlm.nih.gov)
A newly indexed study in the Journal of Veterinary Emergency and Critical Care revisits a core assumption in emergency medicine: what happens when dogs with severe anaphylaxis don’t get epinephrine early. Reviewing 49 canine cases from January 2019 through December 2023, the authors reported a 91.8% survival-to-discharge rate among patients that received late epinephrine or no epinephrine, while also identifying higher shock index and blood lactate as markers tied to poorer outcomes and heavier hospital resource use. (pubmed.ncbi.nlm.nih.gov)
That’s a provocative result because it lands against a well-established treatment backdrop. Across veterinary reviews and clinical guidance, epinephrine is still consistently described as the first-line treatment for anaphylaxis in dogs because it addresses the underlying pathophysiology through vasoconstriction, bronchodilation, improved cardiac output, and suppression of further mediator release. Adjunctive drugs such as antihistamines and glucocorticoids may help with cutaneous signs or later-phase inflammation, but they’re not considered substitutes for epinephrine in shock or rapidly progressive disease. (dvm360.com)
The study’s value, then, is less about overturning protocol than about describing what real-world outcomes looked like in a subset of dogs that, for whatever reason, fell outside ideal early management. Based on the indexed abstract, this was a retrospective medical record review rather than a controlled comparison, and the authors specifically focused on severe anaphylaxis patients who did not receive epinephrine as part of early treatment. That design limits causal conclusions, but it does provide a snapshot of how these cases may still fare under contemporary emergency care. (pubmed.ncbi.nlm.nih.gov)
The prognostic signals may be the most clinically useful part. Higher shock index and elevated lactate were associated with worse outcomes and increased resource utilization, which aligns with broader critical care practice where perfusion markers help guide escalation, monitoring intensity, and client communication. In practical terms, that could make these variables especially relevant in emergency settings when clinicians are trying to distinguish the dog that may stabilize quickly from the one likely to need vasopressor support, blood products, prolonged hospitalization, or closer serial reassessment. (pubmed.ncbi.nlm.nih.gov)
There’s also important context from earlier canine anaphylaxis literature. A 2023 retrospective study of 86 dogs found that respiratory distress, cyanosis, and circulatory shock were associated with nonsurvival, reinforcing that not all canine anaphylaxis behaves the same way and that severity at presentation matters. Other veterinary commentary has emphasized that dogs often present with gastrointestinal and hepatobiliary signs rather than the respiratory-dominant picture more familiar from human medicine, which may contribute to delayed recognition or variation in treatment pathways. (pubmed.ncbi.nlm.nih.gov)
Expert and industry commentary still leans strongly in one direction: use epinephrine first when anaphylaxis is suspected. Recent dvm360 coverage and Clinician’s Brief reviews both reiterate that point, while also acknowledging that steroids and antihistamines continue to be used commonly as add-ons. So the likely takeaway for clinicians isn’t that early epinephrine no longer matters. It’s that retrospective outcome data can reveal a more nuanced reality, where some dogs survive despite deviations from ideal care, and where objective severity markers may help frame prognosis when those deviations happen. (dvm360.com)
Why it matters: For veterinary professionals, this study may be most useful as a risk-stratification paper, not a practice-reversal paper. It adds evidence that severe canine anaphylaxis is survivable even when early epinephrine is missed, but it doesn’t establish equivalence between delayed and prompt treatment. In busy ER settings, the more durable lesson may be to recognize anaphylaxis fast, give epinephrine without letting adjunctive therapies delay it, and use shock index and lactate to identify which patients may need more aggressive monitoring and resource planning. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next step is better comparative evidence, especially multicenter studies that separate early-epinephrine patients from delayed- or no-epinephrine patients, standardize severity scoring, and clarify whether the high survival seen here reflects case selection, supportive care advances, or true flexibility in treatment timing. (pubmed.ncbi.nlm.nih.gov)